(NASDAQ: AIDX) 20/20 Biolabs's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 30.08%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 72.25%.
20/20 Biolabs's earnings in 2026 is -$7,684,628.On average, 3 Wall Street analysts forecast AIDX's earnings for 2026 to be -$7,421,446, with the lowest AIDX earnings forecast at -$7,130,409, and the highest AIDX earnings forecast at -$7,639,724. On average, 3 Wall Street analysts forecast AIDX's earnings for 2027 to be -$5,423,364, with the lowest AIDX earnings forecast at -$5,210,683, and the highest AIDX earnings forecast at -$5,582,875.
In 2028, AIDX is forecast to generate -$6,707,845 in earnings, with the lowest earnings forecast at -$6,444,793 and the highest earnings forecast at -$6,905,135.